aripiprazole / Generic mfg. - LARVOL DELTA

Third-Generation Antipsychotics as Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Narrative Review of Efficacy and Tolerability. (PubMed, Biomedicines) - "Two cohort studies were included on brexpiprazole, with no active or placebo comparator. The current state of evidence supports the clinical utility of TGAs, particularly aripiprazole, in augmenting SRI treatment in patients with refractory OCD. Evidence regarding cariprazine and lumateperone is scarce, but still contributes to the discussion on the use of TGAs in OCD."

Journal • CNS Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Memantine Use in Prolonged Cognitive Sequalae in Pediatric Anti-N-methyl-D-aspartate Receptor Encephalitis: A Three-year Follow-up Case Report and Brief Review. (PubMed, Clin Psychopharmacol Neurosci) - "The patient received immunotherapy including intravenous methylprednisolone, intravenous immunoglobulin, and rituximab, as well as concurrent psychotropics, including valproate and olanzapine/aripiprazole. While 20 mg/day dose of memantine was administering during 6 months, marked improvement was observed in her verbal fluency, academic functioning, and social engagement, that may be associated with post-acute initiation of memantine alongside conventional treatments. This case highlights the evolving understanding of post-autoimmune cognitive rehabilitation and discusses current evidence and theoretical rationale supporting memantine use in complementary treatment of prolonged cognitive dysfunction in the pediatric anti-NMDAR encephalitis."

Journal • Cataplexy • CNS Disorders • Cognitive Disorders • Immunology • Pediatrics • Psychiatry

Multidisciplinary diagnosis and treatment of iatrogenic Cushing syndrome in a patient with obsessive-compulsive disorder. (PubMed, Endocrinol Diabetes Metab Case Rep) - "After the appearance of oral ulcers, the patient uncontrollably used a large amount of chlorhexidine dexamethasone membranes, resulting in iatrogenic Cushing syndrome. The fatty liver and abnormal liver function associated with Cushing syndrome led to the discontinuation of fluvoxamine and aripiprazole for obsessive-compulsive disorder...Multidisciplinary diagnosis and treatment in general hospitals are advantageous or even the only option for improving the prognosis of comorbid mental disorders and somatic diseases. Consultation liaison with psychiatry should be strengthened in general hospitals, especially in the diagnosis and treatment of diseases that are often complicated with psychological symptoms, such as in the endocrinology department."

Journal • CNS Disorders • Cushing’s Disease • Endocrine Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Tic Disorders • Tourette Syndrome

Pharmacologic treatment of tics and Gilles de la Tourette syndrome. (PubMed, Handb Clin Neurol) - "The strongest evidence supports the use of dopamine receptor antagonists, particularly atypical antipsychotics such as aripiprazole and risperidone. However, other agents - including α-2 adrenergic agonists, vesicular monoamine transporter 2 inhibitors, and topiramate - also play an important role in treatment strategies. Pharmacologic management of GTS should be individualized, taking into account symptom severity, functional impact, and the risk-benefit profile of each therapeutic option."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Psychiatry • Tourette Syndrome

Subchronic Exposure to Aripiprazole Subtly Impacts on Rodents' Sperm Quality and Fertility. (PubMed, Basic Clin Pharmacol Toxicol) - "Fertility test was reduced at a dose of 6 mg/kg. These findings suggest that although aripiprazole is effective in treating mental disorders, it may have subtle adverse effects on reproduction, especially on sperm quality and fertility, raising concerns about its indiscriminate use at doses higher than those tested."

Journal • Preclinical • CNS Disorders • Depression • Mental Retardation • Psychiatry • Schizophrenia

A Multicentre, 4-Year Mirror-Image Study Comparing the Effectiveness of Long-Acting Injectable Antipsychotics in the Treatment of Bipolar Disorder: Results From the LAICO Study. (PubMed, Bipolar Disord) - "Study findings suggest that long-acting antipsychotics such as A1M, PP1M, and particularly PP3M are associated with high retention and lower hospitalisation rates after 2 years of treatment in patients with BD."

Clinical • Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Olanzapine in the treatment of schizophrenia in adolescents - mechanisms of action and therapeutic efficacy. (PubMed, Psychiatr Pol) - "Olanzapine is effective in adolescent psychosis and mania but carries substantial metabolic liability. Given no clear efficacy advantage over other SGAs, it is best positioned as a second-line agent in youth, with preference for monotherapy, cautious dosing, and stringent metabolic monitoring. Evidence for benefits on negative and cognitive symptoms in adolescents remains limited."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Dyslipidemia • Metabolic Disorders • Mood Disorders • Pediatrics • Psychiatry • Schizophrenia

Aripiprazole advances delayed sleep-wake rhythm in methamphetamine-treated mice. (PubMed, Chronobiol Int) - "This entrainment was also accompanied by changes in sleep architecture. These findings brought insights into the mechanism how APZ acts on patients with CRSWD, especially with internal desynchronization."

Journal • Preclinical • Sleep Disorder • Sleep Wake Cycle Disorder

STAMD: Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (clinicaltrials.gov) - P1/2 | N=520 | Recruiting | Sponsor: First Affiliated Hospital of Chongqing Medical University | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Establishment of PK/PD Model for Aripiprazole in the Elderly Population and Exploration of Individualized Medication (ChiCTR) - P=N/A | N=24 | Not yet recruiting | Sponsor: Hangzhou First People's Hospital; Hangzhou First People's Hospital

New trial • CNS Disorders • Psychiatry • Schizophrenia

A Randomized Controlled Trial of Brexpiprazole versus Aripiprazole in the Treatment of Major Depressive Disorder with Psychotic Symptoms in Adolescents (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: Shandong mental health center; Shandong mental health center

New trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Comparison of Typical and Atypical Long-Acting Antipsychotics in a Real-World Sample in terms of Treatment Adherence and Factors Influencing Treatment Choice: A One-Year Follow-Up Study. (PubMed, Noro Psikiyatr Ars) - "Adherence was particularly higher with long-acting (LA) aripiprazole and LA paliperidone compared to the other three LAIs (haloperidol, risperidone, and zuclopenthixol) (p<0.05)...Adherence to LAIs administered every four weeks was higher than those administered every two weeks (p=0.014). For patients expected to face challenges with adherence to LAIs, second-generation agents with longer administration intervals may be preferred."

Journal • Real-world evidence • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Comparison of In Vitro Metrics With Real-World Risk of Drug-Induced Parkinsonism Due to Antipsychotic Drugs: Retrospective Cohort Study. (PubMed, JMIR Public Health Surveill) - "Among 44,664 patients from 8 matched cohorts, haloperidol showed the highest DIP risk (HR=4.56, 95% CI 2.29-9.07), whereas aripiprazole exhibited the lowest risk (HR=2.11, 95% CI 1.56-2.86). Integrating receptor-binding kinetics with BBB penetration may provide an in vitro framework that reflects real-world variation in DIP risk among D2R-antagonizing APDs. These findings support the relevance of combining kinetic and central nervous system exposure parameters for early safety evaluation."

Clinical • Journal • Preclinical • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Antipsychotic Treatment and Longitudinal Body Mass Index Trajectories in Youth with and Without Autism Spectrum Disorder. (PubMed, J Clin Med) - "Risperidone and aripiprazole were the most frequently prescribed antipsychotics. Although antipsychotic treatment was initiated earlier in youth with ASD, no clear difference was observed in the rate of BMI z-score change. Differences in weight trajectories underscore the need for metabolic monitoring in antipsychotic-treated youth."

Journal • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mental Retardation • Psychiatry

A Hypersexuality Subset Behavior Induced by Aripiprazole Overdose in an Antipsychotic Naïve Patient: A Case Report and Review of the Literature. (PubMed, Clin Pract) - "Of interest, one month after discontinuing aripiprazole and switching to paliperidone, all the sexual-related symptoms and impulse control disorders resolved. We suggest stronger communication among the clinical teams involved in the patient's care and screening patients for impulse control disorder prior to the administration of aripiprazole and monitoring them during treatment."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • DRD2

Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study. (PubMed, Psychiatry Res) - "Findings indicate dose-dependent real-world effectiveness of antipsychotics in CIP, with most agents performing best at 0.6-<1.4 DDDs/day. These results support optimizing dosing of oral antipsychotic medications for relapse prevention after CIP to balance efficacy and adverse effects."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms. (PubMed, Psychiatry Res) - "Symptom reduction is associated with improved insight, with early changes in positive symptoms exerting the fastest effect. Despite symptom improvement, aripiprazole PDA treatment was linked to less insight gain than DA treatment. These preliminary findings warrant further study."

Journal • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Lumateperone (Caplyta) for adjunctive treatment of depression. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Medication use in Poland for children and adolescents with neurodevelopmental disorders: before, during and after the COVID-19 pandemic - a retrospective pharmacoepidemiological study using national reimbursement data. (PubMed, Front Pharmacol) - "The most substantial increases occurred for sedative and anxiolytic agents (hydroxyzine, diazepam, alprazolam, lorazepam) and antipsychotics (olanzapine, aripiprazole, risperidone, chlorprothixene, haloperidol, levomepromazine), consistent with pandemic related stress, limited access to non-pharmacological care, and possible stockpiling. The COVID-19 pandemic induced broad but temporary increases in pediatric psychotropic drug dispensing, except for ADHD pharmacotherapies, which demonstrated a persistent upward trend. These findings suggest lasting shifts in diagnostic and therapeutic practices and underscore the need for continued monitoring of stimulant use and prescribing appropriateness in pediatric neurodevelopmental care."

Journal • Reimbursement • Retrospective data • US reimbursement • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Infectious Disease • Mental Retardation • Novel Coronavirus Disease • Pediatrics • Psychiatry

Overall and Sex-Based Risk Factors for Hyperprolactinemia in Patients With Schizophrenia: A Retrospective Cohort Study. (PubMed, Curr Neuropharmacol) - "Multiple pharmacological and non-pharmacological factors contribute to HPRL in patients with schizophrenia, with notable sex-specific differences. The potential role of HPRL in breast cancer development among female patients requires further investigation."

Journal • Retrospective data • Breast Cancer • CNS Disorders • Oncology • Psychiatry • Schizophrenia • Solid Tumor

Management challenges in delirium in genetically confirmed long QT syndrome: a case report and discussion. (PubMed, Neuropsychiatr) - "This case illustrates a structured approach to delirium in adolescent LQTS and supports aripiprazole as a pragmatic option when QT-prolonging antipsychotics are contraindicated."

Journal • Acute Lymphocytic Leukemia • Anesthesia • Cardiovascular • CNS Disorders • Critical care • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • Septic Shock

Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole (clinicaltrials.gov) - P=N/A | N=108 | Recruiting | Sponsor: Central South University | N=60 ➔ 108

Enrollment change • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Reversible Lurasidone-Induced Tardive Retrocollis Managed With Aripiprazole. (PubMed, Am J Ther) - No abstract available

Journal

Geschwind syndrome in remitted bipolar affective disorder without MRI brain findings: A case report. (PubMed, Psychiatr Danub) - "She showed limited response to aripiprazole and partial improvement with behavioural interventions. This case highlights the need for increased recognition of GS features in psychiatric populations, independent of structural or seizure-related pathology."

Journal • Bipolar Disorder • CNS Disorders • Epilepsy • Mood Disorders • Psychiatry

Dopamine dysfunction beyond psychosis: Reevaluating its role in depression, anxiety, and obsessive-compulsive disorder. (PubMed, Psychiatr Danub) - "Dopaminergic agents (e.g., bupropion, pramipexole, aripiprazole), neuromodulatory approaches (e.g., TMS, DBS), and biomarker-guided interventions showed promise, particularly in treatment-resistant or subtype-specific presentations. Dopamine dysfunction is a core, transdiagnostic mechanism in depression, anxiety, and OCD, affecting key circuits involved in reward, motivation, and cognitive control. Integrating dopaminergic biomarkers and interventions into psychiatric care may facilitate personalised treatment and improve clinical outcomes."

Journal • Review • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry